Notably, the ALKBH5 PTM sites induced by ROS and KRAS mutations are identical, suggesting a synergistic effect between ROS and KRAS mutations in driving platinum resistance, further reducing NSCLC cell sensitivity to cisplatin. Here, KRAS is linked to non-small cell lung carcinoma.